Multiple Choice
A platelet recipient whose HLA phenotype includes A3, B7; A11, B42 is transfused from a A1, B7; A3, B13 donor. Given the following CREG (Cross-Reactive Groups) , what would you expect the outcome of this transfusion to be? A1-CREG: A1,36,3,9(23,24) ,10(25,26,34,66) ,11, 19(29,30,31,32,33) 28 B7-CREG: B7,42,22(54,55,56) ,27,40(60,61) 13,41,47,48
A) The donor would experience platelet refractoriness because A3 and A11 and B13 and B42 are not cross-reactive.
B) The donor would benefit from this transfusion because A3 and A11 and B13 and B42 are cross-reactive.
C) The recipient would experience platelet refractoriness because A3 and A11 and B13 and B42 are not cross-reactive.
D) The recipient would benefit from this transfusion because A3 and A11 and B13 and B42 are cross-reactive.
Correct Answer:

Verified
Correct Answer:
Verified
Q15: All of the following diseases have been
Q16: What is the most important pretransplant test
Q17: The surface marker, or antigen, detected in
Q18: Which of the following is an example
Q19: A double-lung transplant is indicated in which
Q21: The majority of cross-reactive alloantibodies detect HLA
Q22: A patient who has been presensitized to
Q23: How many targets are required for HLA
Q24: MHC class II molecules are expressed on
Q25: How is complement detected in HLA testing?<br>A)